DARA Bio: A Vastly Undervalued Emerging StorySeeking AlphaData published in the Journal of Supportive Oncology in 2007 (2(2 Suppl 1):13-21) cited a similar near 100% incidence for patients undergoing high-dose chemotherapy with hematopoietic stem cell …
Abbvie, Inc: Pfizer Levoxyl Recall, Humira Provide Near-Term Upside – iStockAnalyst (press release)
iStockAnalyst (press release)Abbvie, Inc: Pfizer Levoxyl Recall, Humira Provide Near-Term UpsideiStockAnalyst (press release)Most of these products are in economically attractive specialty markets (e.g. Elotuzumab in multiple myeloma, and Daclizumab in…
Americord Applauds Promising Research Results Into The Treatment Of Hurler … – PR Leap (press release)
Americord Applauds Promising Research Results Into The Treatment Of Hurler …PR Leap (press release)The retrospective study, which was conducted at the University Medical Center Utrecht, in Utrecht, Netherlands, compared the medical outcomes in patien…
Kols in UP: A life without rights – The Hindu
The HinduKols in UP: A life without rightsThe HinduOver the years, a large number have contracted lung diseases like silicosis and tuberculosis. Some have lost limbs or sustained crippling injuries during the blasting of the rocks. Pannalal Kol, 60, wh…
Compulsory licensing – where is India heading? – IAM (blog) (registration)
|
Compulsory licensing – where is India heading?
IAM (blog) (registration) … were initiated in 2007 by Natco against Pfizer’s drug Sutent (Sunitinib) (see “India to hear patentees’ view in compulsory license cases”), which was used to treat gastrointestinal stromal tumours and Roche’s Tarceva, used in lung cancer treatment. |
Death notices for April 10 – Tulsa World
|
Death notices for April 10
Tulsa World Pawnee – Teresa Louise “Lo” Horsechief, 46, Bureau of Indian Affairs human resources specialist, died Monday in Tulsa. Service 1 p.m. Thursday, Pawnee Nation Roam Chief Center. Poteet. Perry – Elizabeth (Treeman) … In an effort to honor those who … |
BioLineRx Receives Regulatory Approval to Commence Phase II Clinical Trial … – PharmiWeb.com (press release)
BioLineRx Receives Regulatory Approval to Commence Phase II Clinical Trial …PharmiWeb.com (press release)Pre-clinical studies show that BL-8040 is efficient both alone and in combination with the anti-cancer drug Rituximab in reducing bone marrow met…
Immunomedics Develops T-Cell Redirecting Bispecific Antibodies as Potential … – NASDAQ
Immunomedics Develops T-Cell Redirecting Bispecific Antibodies as Potential …NASDAQThe use of bispecific antibodies to redirect T cells for the killing of targeted tumor cells has shown considerable promise both preclinically and clinically. The Comp…
Immunomedics Develops T-Cell Redirecting Bispecific Antibodies as Potential … – Benzinga
Immunomedics Develops T-Cell Redirecting Bispecific Antibodies as Potential …BenzingaThe use of bispecific antibodies to redirect T cells for the killing of targeted tumor cells has shown considerable promise both preclinically and clinically. The Co…
Immunomedics Develops T-Cell Redirecting Bispecific Antibodies as Potential … – GlobeNewswire (press release)
Immunomedics Develops T-Cell Redirecting Bispecific Antibodies as Potential …GlobeNewswire (press release)The use of bispecific antibodies to redirect T cells for the killing of targeted tumor cells has shown considerable promise both preclinically a…